Innovative & Strong Product Portfolio in Cancer Indications

As part of its Business Model, OriBase Pharma has internal R&D programs for drug discovery.

ORB0001

The ORB0001 molecule, currently in pre-clinical development, is a strong inhibitor of Bcr-Abl and Scr kinases. ORB0001 was developed as an alternative to existing treatments of Chronic Myelogenous Leukemiaand Acute Lymphoblastic Leukemia. Contrary to molecules currently in the market, ORB0001 is able to inhibit one of the most frequent resistances in patients, the T315I mutation of the Bcr-Abl kinase.

ORB0002

The ORB0002 molecule is a specific inhibitor of the Src kinase. The signaling induced by this kinase is involved in the proliferation and migration of many cancer cell lines and particularly in those that are resistant to chemotherapeutic agents. Based on its mechanism of action, ORB0002 is an excellent candidate for treating patients with advanced metastatic cancer and refractory to conventional therapy. Currently in its optimization phase, the selectivity of this ORB0002 inhibitor is expected to treat patients who have no alternatives, and with fewer side effects than the kinase inhibitors currently in development.

ORB0003 + ORB0004

ORB0003 is a therapeutic monoclonal antibody and ORB0004 is a new molecular entity, both directed against a tyrosine kinase. Involved in the survival, proliferation, migration, and cell adhesion, this kinase is a target of interest for the treatment of several types of cancers at different stages of progress, and also chemo-resistance. The inhibitors and antibodies directed against this kinase therefore represent potential anticancer substances, specifically for the development of a therapy in metastatic breast cancer and multiple other cancer treatments including the treatment of resistance to chemotherapy. The two therapies can be administered separately or together (dual therapies using monoclonal antibodies associated with small molecule inhibitors of kinase are innovative treatments whose approach was validated for receptor tyrosine kinase).

ORB0005

ORB0005 is a specific inhibitor of a tyrosine kinase. The over-expression and/or appearance of mutations, increasing the activity of this receptor, is associated with a number of cancer types, including lung cancer and many forms of glioblastomas. Mutations in this kinase have been identified; the mutant proteins are targets of new classes of anticancer therapies. ORB0005 is able to inhibit both the wild type and the mutant forms of this protein. Currently in the research phase, ORB0005 will become an alternative to existing treatments that are unable to override the resistances due to mutations in this tyrosine kinase occurring in patients.

Innovative & Strong Product Portfolio in Cancer Indications

As our scientists hold a strong expertise in kinase inhibitors design and optimization, OriBase Pharma’s goal is to develop innovative therapies that have first- or best-in-class potential to treat cancer and other serious diseases related to dysfunctioning kinase.

To achieve this goal we have developed a unique technology platform combining rational in silico drug design to medicinal chemistry and chemistry synthesis of novel scaffolds with high value added to drug discovery since every scaffold we design is aimed to explore unexplored chemistry spaces and to give rise to new intellectual property. Thanks to our expertise in drug discovery and our technology platform, our discovery research capabilities have generated a solid pipeline of product candidates targeting diseases with unmet medical needs such as chemoresistant human cancers.

In addition to our internal capabilities, we have established solid partnerships with academic and private laboratories to expand our resources through innovative drug discovery programs. Currently, we have research programs partnered with Centre of Structural Biochemistry (CBS, Montpellier), Research Institute in Cancer of Montpellier (IRCM, Montpellier), Charles Gerhardt Institute (ICG, Montpellier), Biological Molecule Chemistry and Aroms Laboratory of Nice(LCMBA,Nicce), Ingenious Targeting Laboratory in New York (ITL, New York), Pharmaceutical Research Institute of Albany (PRI, Albany-NY).